sIL-6R levels were further associated with disease parameters in a murine model of systemic lupus erythematosus, and blockade of the IL-6R improved skin lesions in this model [99]. In vitro, IL-6 trans-signaling increases the expression of the tumor-associated antigens CEACAM5 and CEACAM6 in colorectal cancer cells, suggesting that sgp130Fc might be a possible therapeutic option in colon cancer [100]. The gene discussed is IL6R; the disease is systemic lupus erythematosus.